Fig. 1: Sensitivity of T- and B-lymphoid cell lines to NVP-AUY922, 17-AAG and NVP-BEP800. | Blood Cancer Journal

Fig. 1: Sensitivity of T- and B-lymphoid cell lines to NVP-AUY922, 17-AAG and NVP-BEP800.

From: HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias

Fig. 1

a Western blot shows that in Jurkat and Raji cells, levels of phosphorylated SRC and total SRC proteins are more affected after treatment with NVP-BEP800, compared to NVP-AUY922 or 17-AAG. Western blots after 18 h of treatment are shown on the top panel and quantifications on the bottom panel. b XTT viability assay after 48 h of treatment shows that Jurkat and Raji cells are more sensitive to NVP-BEP800, compared to the other two compounds. Data are shown as mean; n = 3 biological replicates. P value measured by one-way Anova test with Tukey’s multiple comparison test; **P < 0.01; ***P < 0.001.

Back to article page